This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
The influence of aquariums on weight in individuals with dementia
This study assessed whether individuals with dementia who observe aquariums increase the amount of food they consume and maintain body weight. The sample included 70 residents in dementia units within 3 extended care facilities in 2 states. The intervention included the introduction of an aquarium into each common dining area. A total increase of 196.9 […]
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial
Dysken, Maurice W.,
Sano, Mary,
Asthana, Sanjay,
Vertrees, Julia E.,
Pallaki, Muralidhar,
Llorente, Maria,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Zachariah, Sally,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Segal, Yoav,
Peduzzi, Peter N.,
Guarino, Peter D.
Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]
“Learning to become a family caregiver” efficacy of an intervention program for caregivers following diagnosis of dementia in a relative
Ducharme, F. C.,
Levesque, L. L.,
Lachance, L. M.,
Kergoat, M.-J.,
Legault, A. J.,
Beaudet, L. M.,
Zarit, S. H.
Purpose: The purpose of this experimental study was to test the efficacy of a psychoeducational individual program conceived to facilitate transition to the caregiver role following diagnosis of Alzheimer disease in a relative.; Design and Methods: Caregivers were recruited in memory clinics and randomized to an experimental group (n = 62) or a control group […]
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, Richard,
Rominger, Axel,
Bartenstein, Peter,
Barkhof, Frederik,
Blennow, Kaj,
Förster, Stefan,
Winter, Yaroslav,
Bach, Jan-Philipp,
Popp, Julius,
Alferink, Judith,
Wiltfang, Jens,
Buerger, Katharina,
Otto, Markus,
Antuono, Piero,
Jacoby, Michael,
Richter, Ralph,
Stevens, James,
Melamed, Isaac,
Goldstein, Jerome,
Haag, Stefan,
Wietek, Stefan,
Farlow, Martin,
Jessen, Frank
Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study
de Waal, Hanneke,
Stam, Cornelis J.,
Lansbergen, Marieke M.,
Wieggers, Rico L.,
Kamphuis, Patrick J. G. H.,
Scheltens, Philip,
Maestú, Fernando,
van Straaten, Elisabeth C. W.
Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]
Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease
Davenward, Samantha,
Bentham, Peter,
Wright, Jan,
Crome, Peter,
Job, Deborah,
Polwart, Anthony,
Exley, Christopher
There has been a plausible link between human exposure to aluminum and Alzheimer’s disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of […]